[go: up one dir, main page]

WO2008048691A3 - Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders - Google Patents

Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders Download PDF

Info

Publication number
WO2008048691A3
WO2008048691A3 PCT/US2007/022413 US2007022413W WO2008048691A3 WO 2008048691 A3 WO2008048691 A3 WO 2008048691A3 US 2007022413 W US2007022413 W US 2007022413W WO 2008048691 A3 WO2008048691 A3 WO 2008048691A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
lipectomy
post
fat deposition
ectopic fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/022413
Other languages
French (fr)
Other versions
WO2008048691A2 (en
Inventor
Howard E Greene
Andrew A Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of WO2008048691A2 publication Critical patent/WO2008048691A2/en
Publication of WO2008048691A3 publication Critical patent/WO2008048691A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Leptin, leptin analogs, leptin derivatives, and other leptin agonists are used to treat subjects with post-lipectomy ectopic fat deposition and associated metabolic abnormalities or disorders. Such leptin, leptin analogs, derivatives, and other leptin agonists are also used in the preparation of medicaments for treating or preventing ectopic fat deposition and associated metabolic abnormalities or disorders in such subjects. Such ectopic fat deposition and metabolic abnormalities conditions or disorders include, but are not limited to, hepatic steatosis, hypertriglyceridemia, dyslipidemia, cardiovascular disease, insulin-resistance, and diabetes mellitus.
PCT/US2007/022413 2006-10-18 2007-10-18 Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders Ceased WO2008048691A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85281106P 2006-10-18 2006-10-18
US60/852,811 2006-10-18

Publications (2)

Publication Number Publication Date
WO2008048691A2 WO2008048691A2 (en) 2008-04-24
WO2008048691A3 true WO2008048691A3 (en) 2008-07-24

Family

ID=39309590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022413 Ceased WO2008048691A2 (en) 2006-10-18 2007-10-18 Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders

Country Status (1)

Country Link
WO (1) WO2008048691A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028457A (en) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 How to treat neurodegenerative disorders associated with nerve fiber knots
WO2009149379A2 (en) * 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US20130023469A1 (en) * 2009-09-22 2013-01-24 Hadasit Medical Research Services & Development Ltd. Leptin for use in increasing liver regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO2003034996A2 (en) * 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO2003034996A2 (en) * 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US20050020496A1 (en) * 2001-10-22 2005-01-27 Amgen Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. B. HAUSMAN ET AL: "Compensatory Growth of Adipose Tissue After Partial Lipectomy: Involvement of Serum Factors", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 229, 2004, pages 512 - 520, XP002478543 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; October 1998 (1998-10-01), MATARASSO A ET AL: "The impact of liposuction on body fat", XP002478545, Database accession no. EMB-1998345535 *
E. D. JAVOR ET AL: "Long-Term Efficacy of Leptin Replacement in Patients with Generalized Lipodystrophy", DIABETES, vol. 54, July 2005 (2005-07-01), pages 1994 - 2002, XP002478542 *
PLASTIC AND RECONSTRUCTIVE SURGERY 199810 US, vol. 102, no. 5, October 1998 (1998-10-01), pages 1686 - 1689, ISSN: 0032-1052 *
R.V. WEBER ET AL: "Subcutaneous lipectomy causes a metabolic syndrome in hamsters", AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 279, 2000, pages 936 - 943, XP002478544 *

Also Published As

Publication number Publication date
WO2008048691A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
CL2007002347A1 (en) COMPOUNDS DERIVED FROM PHENYLL, PYRIDINE AND QUINOLINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES, DISORDERS IN THE TOLERANCE OF GLUCOSE, OBESITY, CROHN'S DISEASE, SICK
PL2211842T3 (en) An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
WO2010138899A3 (en) Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
WO2008108958A8 (en) Benzimidazole derivatives and methods of use thereof
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2006105501A3 (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2007124461A3 (en) Glp-1 compounds
WO2010048207A3 (en) Aryl gpr120 receptor agonists and uses thereof
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2008153788A3 (en) Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2012054526A8 (en) Chemosensory receptor ligand-based therapies
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
IL196561A (en) Use of sulfamide and glinide atp-sensitive potassium channel ligands for the preparation of pharmaceutical compositions for treating diabetes mellitus and/or neuropsychological disorders
WO2012094462A3 (en) Heterocyclic compounds for the inhibition of pask
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861474

Country of ref document: EP

Kind code of ref document: A2